IMPELLA, the world’s smallest heart pump is the only non-surgical heart pump FDA-approved for patients undergoing high-risk PCI and those with cardiogenic shock. The Impella heart pump helps ensure blood flow is maintained to critical organs such as the brain and kidneys during a PCI procedure.
It is considered one of the most revolutionary inventions for treating heart diseases in recent times.
India is the 5th country in the world where Impella miniaturized Heart Pump is launched which shall save many lives.

Impella Heart Recovery Program, which was launched in several hospitals in India with the goal of recovery of native heart, has saved many lives worldwide in sub-group of patients undergoing Protected PCI & AMI -Cardiogenic Shock, Myocarditis, Cardiomyopathy, and Post Cardiotomy Cardiogenic Shock.

It has also enabled patients who are waiting for a Heart Transplant to survive till they get a donor Heart.

Even in patients with cardiogenic shock treated with an invasive approach (cardiac catheterization, angioplasty, and coronary bypass surgery), in-hospital mortality approaches 40%. By this, Impella saves the lives of such people by improving the heart muscle function that enables a patient to sustain quality of life at home with their native heart.

The Impella Ventricular Support System acts as a blood pump that effectively bypasses the left ventricle, it supports blood pressure and provides increased blood flow to critical organs in patients with cardiogenic shock. This allows the left ventricle to rest and hopefully recover and resume pumping without support. Clinical evidence demonstrated that 58% of patients with cardiogenic shock who received the Impella device survived the procedure, and 67% of patients who left the hospital experienced myocardial recovery (they did not have another heart failure event) within 30 days of the procedure.

Read latest news related to Interventional Cardiology